Transcriptomic Study of Cutaneous Fibroblasts in Scleroderma

Sponsor
Centre Hospitalier Universitaire Dijon
Study ID
NCT07256418
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Accepted

Interventions

  • Skin samples — PROCEDURE
    * Scleroderma group: skin biopsy for scleroderma patients * Control group: recovery of resected tissue from patients undergoing plastic, reconstructive and aesthetic surgery.
  • Analysis of fibroblasts — OTHER
    Analysis of samples by RNA sequencing

Study Details

Scleroderma is a complex connective tissue disease involving three interconnected pathophysiological axes: vascular hyperactivity and remodelling, immune system dysfunction and over-activation of fibroblasts at the origin of the fibrosis process in the skin and organs. Given that this pathology occurs preferentially in mature subjects, it is possible to suggest a potential inductive role for senescent fibroblasts, which would be responsible for activating and/or maintaining the immune response and systemic inflammation. Our hypothesis is that fibroblasts play a predominant role in the genesis and maintenance of this pathology.

Key Dates

Start date
Jan 26, 2026
Status verified
Jan 2026
Primary completion
Jan 31, 2027
Completion
Jan 31, 2027

Study Design

Enrollment
60 participants (estimated)

Arms

  • Arm: scleroderma
    People with systemic scleroderma
  • Arm: Control
    People undergoing plastic, cosmetic and reconstructive surgery

Primary Outcome Measure

genes involved in the various cell activation and signalling pathways [ Time Frame: through study completion, an average of 12 months ]

Central Contacts

Related Studies